SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The upcoming Phase 3 REGAL trial readout for SELLASs AML treatment GPS dominates discussion, with traders focused on the binary clinical catalyst. Bulls anticipate strong results, while skeptics cite the stocks sharp volatility and warn of failure risk or a sell-the-news reaction; claims of short-term manipulation remain speculation.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summits FDA review of ivonescimab for EGFR-mutated lung cancer is driving a binary-outcome debate over approval versus a possible rejection or request for more evidence. Bulls point to strong progression-free-survival results and encouraging survival trends, while bears focus on the FDAs stated need for statistically significant overall-survival evidence; recent weakness has also prompted speculation about a negative outcome, though traders say price action alone is not proof.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQs sharp after-hours drop drew attention as traders linked the move to the FAAs nationwide ground stop after communications problems, while speculation about a cyberattack or AI involvement remained unverified. The discussion also reflected wider pressure on tech and AI stocks tied to uncertainty around Nvidia, with traders divided between seeing the selloff as an overreaction and expecting further weakness.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians volatile, weak share performance is driving debate, with traders blaming heavy short-selling and persistent selling pressure while bulls point to improving deliveries, the R2 ramp, and upcoming autonomy developments. Sentiment remains split between concern over cash burn and execution and hopes that the companys growth initiatives can improve its outlook.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Reported takeover discussions involving Silver Lake and Saudi Arabias PIF are driving speculation, though no deal is confirmed; traders disagree over whether a potential offer would undervalue Unity. The interest is reinforced by strong quarterly results and the companys first GAAP-profitable quarter, with bullish call activity and breakout chatter alongside skepticism about the rally.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius selloff is being tied to its earnings outlook and delays in activating third-party data-center capacity, which push expected revenue into a later period and have prompted analyst price-target cuts. Traders are divided between viewing the execution and heavy-capex concerns as a reason for further downside and treating the drop as an overreaction, with broader weakness in AI and neocloud stocks adding pressure.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

Reports of an FAA nationwide ground stop tied to air-traffic-control communications problems are drawing attention to AAL, with traders discussing possible departure delays and rerouting. Some characterize the disruption as brief, while speculation about its cause remains unverified.

HawKeye 360, Inc. engages in the provision of defense technology. It offers spectrum monitoring, maritime intelligence, air defence radar monitoring, GNSS interference detection, and communications mapping. Its costumers include a wide range of commercial, government and international entities. The company was founded by Charles T. Clancy, Robert G. McGwier, Chris DeMay and John Serafini in 2015 and is headquartered in Herndon, VA.

HawkEye 360 Inc.

HAWK is drawing attention after reporting record third-quarter revenue and raising its full-year outlook, with traders also highlighting international growth, contract demand, and plans for lower-cost satellites. The community reaction is broadly bullish on the results and rally, though claims of institutional accumulation and further upside remain speculative.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs abrupt departure is driving debate over Nvidias leadership transition, with traders speculating about his return and possible successors while others worry about leadership uncertainty and scrutiny of chip exports to China. Bulls argue Nvidias business remains strong and point to earnings, while bears see unresolved risks weighing on confidence.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos stronger-than-expected quarterly results and raised full-year outlook, driven largely by demand for its Wegovy pill, have fueled renewed buying interest. Traders are debating whether the oral drugs momentum can support a sustained recovery amid Lilly competition and concerns about Novos execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and Madrigal

TGTX, BCRX, INSM and MDGL are expanding commercial reach through rising therapy sales, broader patient access and potential new indications.

4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth

TGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.

BioCryst Pharma Q3 2026 Earnings Call Transcript

BioCryst Pharma (NASDAQ:BCRX) reported third-quarter financial results on Wednesday. The transcript from the company's third-quarter earnings call has been provided below.Benzinga APIs provide real-time access toread more...

BioCryst Pharmaceuticals (BCRX) Surpasses Q3 Earnings and Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of +40.00% and +8.32%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Bioventus (BVS) Matches Q3 Earnings Estimates

Bioventus (BVS) delivered earnings and revenue surprises of 0.00% and -4.74%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

The consensus price target hints at a 137.9% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings Growth

Pacira BioSciences (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?

Here is how AxoGen (AXGN) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 Biotech Stocks to Watch as Potential Takeover Targets

Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>RBC downgraded BioCryst to ‘Sector Perform’ from ‘Outperform,’ according to The Fly.</li><li>BioCryst expects revenue from Orladeyo between $625 million and $645 million in full-year 2026.</li><li>The brokerage sees longer-term potential from BioCryst’s second HAE drug, Navenibart.</li></ul>BioCryst Pharmaceuticals (BCRX) was in the spotlight on Thursday, after RBC Capital said the biotech firm faces a “challenging near-term outlook” after Pharvaris (PHVS) published strong late-stage data for hereditary angioedema (HAE) therapy.RBC downgraded BioCryst to ‘Sector Perform’ from ‘Outperform’ and lowered the price target to $11 from $13, according to The Fly. BCRX shares are currently trading near $8.The firm said Pharvaris’ experimental therapy could pressure its key hereditary angioedema drug, Orladeyo, and expects the shares to remain range-bound until new catalysts emerge.At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/BCRX">BCRX shares</a> were down 8%, heading for their fifth straight session of losses.&nbsp;The stock has already shed more than 20% of its value so far over the five sessions.<h2 class="st-heading-2">Pharvaris Data Raises Competition</h2>The downgrade follows Phase 3 results for Pharvaris’ Deucrictibant XR, an experimental once-daily pill designed to prevent HAE attacks. HAE is a rare genetic condition that causes episodes of swelling in different parts of a child’s body, including the face, hands, and feet.Pharvaris said the drug reduced monthly attacks by 83% compared with placebo in its Chapter-3 study. The drug was generally well tolerated, and the company plans to begin seeking regulatory approvals in the first half of 2027.<h2 class="st-heading-2">RBC Expects Revenue Tailwinds For Orladeyo</h2>RBC believes the results could lead patients to switch away from Orladeyo and reduce the drug’s longer-term revenue to about $400 million to $450 million.The drug generated sales of over $600 million in full-year 2025, and the company expects revenue of $625 million to $645 million in 2026.Still, RBC sees longer-term potential from BioCryst’s second HAE drug, Navenibart. The Phase 3 study is fully enrolled, with six- and 12-month efficacy data expected in the third quarter of 2027.<h2 class="st-heading-2">Retail’s Take On BCRX</h2>Retail sentiment surrounding BCRX on Stocktwits remained ‘bullish’ over the past 24 hours, amid ‘high’ message volumes.One user opined that the “execution risk just rose for Navenibart.”<stembedurl>https://stocktwits.com/Cap_00/message/663973370</stembedurl>The stock has gained around 4% so far in 2026.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/brent-futures-top-105-per-barrel-as-houthis-seize-strategic-red-sea-port-opec-cuts-2026-demand-outlook/cZtagdoRJ62">&nbsp;Brent Futures Top $105 Per Barrel As Houthis Seize Strategic Red Sea Port — OPEC Cuts 2026 Demand Outlook</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CANADA - 2025/10/14: In this photo illustration, the BioCryst Pharmaceuticals (Bio Cryst) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

RBC Capital said it expects revenue tailwinds for BioCryst’s Orladeyo drug after Pharvaris posted strong Phase 3 data for HAE therapy.

SPDR S&P Biotech ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$7.61
Prev Close	$7.68
Open	$7.67
Dividend Yield	0.00%
50-Day Moving Average	$8.28
Beta	0.97
Avg. Volume	5.06M
PE Ratio	-5.40

52-Week High	$11.22
52-Week Low	$6.23
Market Capitalization	$1.98B
EPS (Annual)	$1.21
Price to Book	-4.95
Revenue Per Employee	$2.01M

Feed

News

Sentiment

Earnings

Fundamentals

Info

BCRX Fundamentals